PHARMACEUTICAL TABLET TECHNOLOGY
Comprehensive Industrial Technical Notes: Preformulation, Formulations, Granulation Methods, Quality Control & Plant GMP Compliance
1. Definition & Industrial Overview
A Tablet is defined as a solid unit dosage form containing active pharmaceutical ingredients (APIs) with or without suitable pharmaceutical excipients, manufactured either by direct compression, wet/dry granulation, or molding methods.
Industrial Advantages of Tablets
- Unit Dose Precision: Provides the most precise dose and lowest dosage variability among all oral dosage forms.
- Cost-Effective Manufacturing: Highest production speed and lowest cost per unit dosage form on modern rotary tablet presses (exceeding 500,000 tablets/hr).
- Chemical & Physical Stability: Enhanced physical and chemical drug stability compared to liquid oral dosage forms.
- Packaging & Shipping Efficiency: Compact, lightweight, and easy to package in tamper-evident blisters or bottles for global distribution.
- Patient Compliance: Simple administration, convenient for self-medication, and taste-masked via film/sugar coating.
Industrial Limitations
- Biopharmaceutical Challenges: Poorly water-soluble APIs (BCS Class II & IV) suffer from slow dissolution rates and low bioavailability.
- Compression Physics Risk: Cohesive or elastic materials resist compaction, leading to capping, lamination, or picking during high-speed compression.
- Patient Subgroup Restrictions: Difficult administration for pediatric, geriatric, and unconscious patients.
2. Classification and Types of Pharmaceutical Tablets
A. Tablets Ingested Orally
- Uncoated / Standard Compressed Tablets (CT): Single-compression cycle of API and excipients; rapid breakdown and dissolution in gastric fluid.
- Multiple Compressed Tablets (MCT): Prepared by subjecting core to more than one compression cycle.
- Layered Tablets: Two or three distinct parallel layers compressed sequentially to separate chemically incompatible APIs or achieve dual-release (immediate + sustained) profiles.
- Compression-Coated Tablets: Core tablet surrounded by an outer compressed coat; ideal for separating incompatible materials or creating delayed-release cores.
- Sustained / Extended-Release Tablets (ER/SR): Formulated with hydrophilic/hydrophobic matrix polymers (e.g., HPMC, Ethylcellulose) to release drug continuously over 12–24 hours, reducing dosing frequency.
- Enteric-Coated Tablets: Coated with gastric-acid resistant polymers (e.g., Cellulose Acetate Phthalate / CAP, Eudragit L100) that remain intact in gastric fluid (pH 1.2) but dissolve rapidly in intestinal fluid (pH > 5.5).
- Sugar-Coated Tablets: Multi-step aqueous sugar application to mask offensive taste/odor, prevent oxidation, and enhance elegance (adds 30–50% total weight).
- Film-Coated Tablets: Coated with a thin polymer film (e.g., HPMC, HPC) adding < 2–3% to total weight while offering mechanical protection and moisture barrier.
- Chewable Tablets: Formulated to be chewed prior to swallowing; utilizes smooth-tasting diluents (Mannitol, Sorbitol) without disintegrants (e.g., Antacids, Vitamins).
B. Tablets Administered in the Oral Cavity
- Buccal Tablets: Placed between cheek and gum; slow erosion delivers drug directly into systemic circulation via buccal mucosa, bypassing hepatic first-pass metabolism.
- Sublingual Tablets: Placed under the tongue; rapid systemic absorption through mucosal capillary bed (e.g., Nitroglycerin for angina pectoris).
- Lozenges / Troches: Hard candy or compressed matrices designed to dissolve slowly in mouth for local therapeutic action in the throat.
- Dental Cones: Minor compressed plugs placed in dental sockets following extraction to prevent bacterial infection or hemorrhage.
C. Tablets Administered by Alternate Routes
- Vaginal Tablets (Pessaries): Uncoated bullet or ovoid tablets designed for slow localized drug release in the vaginal tract.
- Subcutaneous Implants: Sterile, cylindrical rods surgically implanted subcutaneously for long-term extended systemic drug release (6–12 months).
D. Tablets Used to Prepare Solutions
- Effervescent Tablets: Contains active drug, organic acids (citric/tartaric acid), and sodium bicarbonate; reacts rapidly in water producing carbon dioxide (CO2) gas for pleasant, fast dissolution.
- Soluble / Dispensing Tablets: Completely water-soluble tablets intended to be dissolved in water by a pharmacist or patient immediately prior to administration.
- Tablet Triturates: Small, cylindrical molded or compressed discs containing potent drugs mixed with lactose/sucrose diluents.
3. Key Excipients in Tablet Formulations
Excipients are inactive functional additives combined with the API to facilitate tableting, improve physical integrity, enhance flowability, and control drug release.
| Excipient Class | Primary Function | Typical Examples | Usage Range & Key Notes |
|---|---|---|---|
| Diluents (Fillers) | Add bulk volume to achieve target tablet size/weight | Microcrystalline Cellulose (Avicel PH101/102), Lactose Monohydrate, Dicalcium Phosphate (DCP), Mannitol | 10 – 80% (MCC acts as direct compression binder; Mannitol used for chewable) |
| Binders (Adhesives) | Provide cohesive strength to granules/powders during compaction | Polyvinylpyrrolidone (PVP K30), Starch Paste (5-10%), HPMC 2910, Gelatin, Acacia | 1 – 5% (Wet binders added in solution; dry binders mixed in powder phase) |
| Disintegrants & Superdisintegrants | Facilitate tablet breakdown into smaller fragments upon fluid contact | Corn Starch (5-15%), Crospovidone (1-5%), Croscarmellose Sodium (Ac-Di-Sol, 1-5%), Sodium Starch Glycolate (Explotab, 2-8%) | 1 – 15% (Superdisintegrants swell rapidly by 10-20x without forming gel) |
| Lubricants | Reduce friction between tablet edge and die wall during ejection | Magnesium Stearate, Stearic Acid, Sodium Stearyl Fumarate (SSF), Calcium Stearate | 0.25 – 1.0% (Hydrophobic; over-mixing reduces dissolution rate) |
| Glidants | Enhance flowability of powder/granule blend into die cavity | Colloidal Silicon Dioxide (Aerosil 200), Pure Talc, Corn Starch | 0.1 – 0.5% (Reduces inter-particulate friction) |
| Anti-Adherents | Prevent powder adhesion to punch faces and die walls | Talc, Corn Starch, Magnesium Stearate | 0.5 – 2.0% (Eliminates picking and sticking) |
| Colorants & Flavors | Improve visual elegance, brand identification, and taste masking | FD&C Dyes, Synthetic Iron Oxides (Yellow/Red), Menthol, Sucralose, Peppermint | 0.01 – 0.5% (Light-stable lakes preferred for tablets) |
4. Preformulation Studies (Lachman Framework)
Preformulation is the fundamental phase where the physical and chemical properties of a drug substance are thoroughly investigated prior to formulation development to ensure stable, scalable manufacturing.
A. Organoleptic & Solid-State Properties
- Visual Appearance & Color: Assessed under standardized lighting to detect impurities or batch-to-batch variation.
- Particle Size & Surface Area: Measured via laser diffraction or sieve analysis; dictates powder flow, dissolution kinetics, and blend homogeneity.
- Polymorphism & Crystallinity: Evaluated using Differential Scanning Calorimetry (DSC) and X-Ray Powder Diffraction (XRPD). Metastable forms offer higher solubility but lower thermodynamic stability.
B. Powder Flow & Bulk Compression Metrics
- Bulk Density (Db): Db = Mass / Bulk Volume (Vb) [g/mL]
- Tapped Density (Dt): Dt = Mass / Tapped Volume (Vt) [g/mL] (measured after 1,250 mechanical taps)
- Carr’s Compressibility Index (CI): CI = [(Dt – Db) / Dt] x 100
- Hausner Ratio (HR): HR = Dt / Db
- Angle of Repose (θ): tan(θ) = Height / Radius (h/r) of fixed powder cone
| Flow Character | Carr’s Index (CI %) | Hausner Ratio (HR) | Angle of Repose (θ) |
|---|---|---|---|
| Excellent | < 10 % | 1.00 – 1.11 | < 30° |
| Good | 11 – 15 % | 1.12 – 1.18 | 31° – 35° |
| Fair (Passable) | 16 – 20 % | 1.19 – 1.25 | 36° – 40° |
| Poor | 21 – 25 % | 1.26 – 1.34 | 41° – 45° |
| Very Poor / Extremely Cohesive | > 35 % | > 1.60 | > 56° |
C. Solution & Stability Profiling
- Intrinsic Dissolution Rate (IDR): Dissolution rate of pure API under constant surface area, temperature, and agitation (mg/cm²/min).
- pKa & pH-Solubility Profile: Determines ionization state across gastrointestinal pH range (pH 1.2 to 7.5).
- Partition Coefficient (log P): Octanol/water partition coefficient indicating lipophilicity and membrane permeability.
- Hygroscopicity (DVS): Dynamic Vapor Sorption analysis to classify moisture absorption at various relative humidities (RH).
- Drug-Excipient Compatibility: Binary mixtures (1:1 API to excipient) stressed at 40°C / 75% RH for 2–4 weeks; analyzed using DSC thermal overlaps, FTIR spectra shifts, and Isothermal Microcalorimetry.
5. Tablet Manufacturing Processes & Technology
A. Direct Compression (DC)
- Process Flow: Raw Material Sifting → Dry Powder Blending (API + Direct Compression Fillers) → Lubrication → Tableting.
- Key Advantages: Fastest cycle time, lowest manufacturing cost, eliminates heat/moisture exposure (ideal for thermo-labile APIs).
- Key Limitations: Unsuitable for high-dose drugs with poor flow or compressibility; segregation risk during transfer.
B. Wet Granulation (WG)
- Process Flow: Raw Material Sifting → Dry Blending → Wet Massing (Binder Addition) → Wet Granulation → Fluid Bed Drying (FBD) → Dry Screening/Milling → Lubrication → Tableting.
- Pharmacist, Drug Inspector & GPAT Notifications
- Free Study Material & Practice Test Series
🎯 Never Miss Pharma Job Alerts & Exam Prep Material!
Subscribe to VigyanLok Updates and get the latest Government & Private Pharmacy Jobs, Free Mock Tests, Notes, and Exam Notifications sent directly to your email.